U.S. Retail REITs Stock News

Investors may be wondering if AbbVie at around US$202 a share still offers value, or if most of the opportunity has already played out. The stock has recently seen mixed returns, with a 4.1% decline over the last 7 days, a 1.8% decline over 30 days, and an 11.6% decline year to date. Over 1 year and 5 years, the returns stand at 12.8% and 109.7% respectively. Recent headlines have focused on AbbVie's position in the large-cap pharmaceuticals space and how investors are weighing its long term...

Lumentum Holdings Inc. reported past fiscal third-quarter 2026 results with sales rising to US$808.4 million and net income to US$144.2 million, alongside strong guidance calling for fourth-quarter net revenue between US$960 million and US$1.01 billion. The surge in profitability was driven largely by demand for AI and cloud-related optical components, supported by expanded manufacturing capacity and a multiyear US$2.00 billion preferred equity investment and supply agreement with...

If you are trying to work out whether DraftKings stock looks attractively priced or too expensive at today’s levels, you will want more than just the latest share price in front of you. The stock recently closed at US$25.22, with returns of 8.1% over 7 days and 9.9% over 30 days, while year to date and 1 year returns of negative 29.3% and negative 28.7% show a very different picture over a longer window. Recent headlines around DraftKings have largely focused on the broader US sports betting...

Earlier this week, Bernstein analyst Aneesha Sherman upgraded Deckers Outdoor to a hold rating, reflecting greater confidence in the company’s operating profile and brand positioning. This shift in analyst stance comes as Deckers’ core brands, particularly HOKA and UGG, continue to underpin strong fundamentals and attract growing investor attention. We’ll now examine how this improved analyst sentiment, anchored in the strength of HOKA and UGG, reshapes Deckers Outdoor’s investment...

Johnson & Johnson (NYSE:JNJ) reported positive Phase 2b results for its investigational co antibody therapy JNJ-4804 in highly refractory ulcerative colitis and Crohn's disease. The company also released positive Phase 3 data for TREMFYA in perianal fistulizing Crohn’s disease, a difficult form of inflammatory bowel disease. Johnson & Johnson plans to advance JNJ-4804 and related programs into Phase 3 trials to address high unmet needs in inflammatory bowel diseases. For investors tracking...

In early May 2026, Solaris Energy Infrastructure’s subsidiary completed the pricing of US$1.30 billion of 6.375% senior unsecured notes due 2031, intended to refinance existing borrowings, cover fees and expenses, and support general corporate purposes including growth capital expenditures. This financing followed a strong first quarter 2026, when Solaris reported sharply higher revenue and net income and secured a new 10-year agreement to supply over 600 MW of power capacity and...

UK Financial Conduct Authority opens a competition investigation into Visa, Mastercard, and PayPal over suspected anti competitive conduct involving card scheme and processing services. Visa (NYSE:V) extends its stablecoin settlement pilot to nine blockchains and scales its Agentic Ready program for AI driven commerce to partners worldwide. The developments highlight both rising regulatory scrutiny of large payment networks and Visa’s continued push into digital assets and AI enabled payment...

Event context and recent stock performance TransDigm Group (TDG) stock has been on the move recently, with a roughly 7% gain over the past week. This adds to a month-long rise of about 6%, even as the past 3 months show a 3% decline. See our latest analysis for TransDigm Group. At a share price of $1,241.98, TransDigm Group’s recent 7 day and 30 day share price returns contrast with its weaker year to date move. The 3 year total shareholder return of 82.33% and 5 year total shareholder return...

Q1 results and new shelf registration Beyond Meat (BYND) has drawn fresh attention after reporting first quarter 2026 results, which showed a reduced net loss alongside lower sales. This was followed shortly by a US$10.4 million shelf registration tied to an employee stock ownership plan. See our latest analysis for Beyond Meat. The stock has moved sharply around the Q1 update and ESOP shelf filing, with a 30-day share price return of 53.93% contrasting with a 1-year total shareholder return...

Amkor Technology (AMKR) is back in focus after reporting record Q1 2026 results, issuing upbeat Q2 guidance, and pairing a new share buyback with fresh leveraged ETFs tied to its stock. See our latest analysis for Amkor Technology. The latest earnings beat, upbeat Q2 guidance and fresh leveraged ETFs have come alongside sharp share price moves, with a 51.76% 1 month share price return and a 68.38% year to date share price return. The 1 year total shareholder return of 306.25% and 5 year total...

In the past week, Revolution Medicines reported first-quarter 2026 results showing a wider net loss of about US$453.82 million and basic and diluted losses per share of US$2.29, alongside updated 2026 expense guidance reflecting higher research, development and commercial preparation spending. At the same time, the company highlighted late-stage pancreatic cancer data for lead candidate daraxonrasib and progress toward global regulatory submissions, sharpening the focus on how its expanding...

Wondering if Nu Holdings is still good value at around US$14.26, or if the easy gains are already behind it? This overview sets you up to judge the stock price with a clear, structured lens. The stock has returned 11.4% over the last year and a very large 3 year gain, even as the year to date move sits at a 16.2% decline, which can change how the market views both its growth potential and risk. Recent headlines have focused on Nu Holdings as a large listed Latin American digital bank, often...

Aurinia Pharmaceuticals (AUPH) opened Q1 2026 with total revenue of US$77.7 million, basic EPS of US$0.26, and trailing 12 month EPS of US$2.25, following a year in which earnings grew very sharply and the company moved to a 100% net margin. The company has seen quarterly revenue move from US$59.9 million in Q4 2024 to US$62.5 million in Q1 2025 and then to US$77.7 million in Q1 2026, while basic EPS has shifted over the same period from US$0.01 to US$0.17 and then to US$0.26. This has set up...

Deere (NYSE:DE) has partnered with Every Man Jack to launch a co branded grooming line. The limited edition products bring the John Deere brand into the consumer personal care market for the first time. The collection is available exclusively at Walmart, targeting a broad retail audience. For a company known primarily for agricultural and construction equipment, this move pulls the John Deere brand into a very different aisle. Deere already sits at the intersection of farming, construction,...

Why tight egg supply is back in focus for Cal-Maine Foods (CALM) Recent commentary points to tight egg supply and steady consumer demand supporting Cal-Maine Foods (CALM), with pricing power, margins and industry consolidation drawing fresh attention to how the stock reflects these conditions. See our latest analysis for Cal-Maine Foods. At a share price of US$75.74, CALM has seen a 90 day share price return of 8.23% decline and a 1 year total shareholder return of 12.14% decline, even though...

Zoetis (NYSE:ZTS) has cut its full year guidance after a sharp downturn in its U.S. companion animal business. Management points to higher price sensitivity among pet owners, fewer veterinary visits, and more generic competition as key pressures. The company is refocusing on integrated solutions, tighter cost controls, and operational efficiency as part of a broad reset. For investors, the reset lands on top of a steep share price pullback. Zoetis now trades at $87.31, with the stock down...

For investors wondering if Krystal Biotech at around US$296.70 is still offering value or if the easy gains are behind it, this article walks through what the current price may be implying. The stock has shown strong share price moves, with returns of 13.1% over 7 days, 12.4% over 30 days, 20.2% year to date, 116.3% over the last year, 228.5% over 3 years, and 374.4% over 5 years. These price moves sit against a backdrop of ongoing attention on Krystal Biotech's position in the...

In late April 2026, Federated Hermes reported first-quarter revenue of US$478.96 million and net income of US$96.38 million, alongside a quarterly dividend increase to US$0.38 per share payable on May 15, following its Annual General Meeting. Just days later, the company filed a US$270.60 million shelf registration for 5,000,000 Class B common shares linked to its employee stock ownership plan, underscoring an emphasis on employee alignment and capital-raising flexibility. We’ll now examine...

If you are wondering whether International Business Machines stock is pricing in too much optimism or leaving value on the table, the starting point is understanding how its current share price compares with underlying fundamentals. The stock recently closed at US$231.31, with returns of 0.1% over 7 days, a 5.6% decline over 30 days, a 20.6% decline year to date, and gains of 6.0% over 1 year, 110.8% over 3 years and 104.3% over 5 years. These figures set the backdrop for any valuation...

Ultragenyx Pharmaceutical Inc. reported past first-quarter 2026 results with revenue of US$136 million, a wider net loss of US$185 million, and reaffirmed its 2026 revenue guidance of US$730 million to US$760 million while remaining on a stated path toward profitability in 2027. Management also highlighted potential 2026 approvals for two gene therapies and key late-stage data for its Angelman syndrome program, underscoring how clinical and regulatory milestones are central to its...

American Express was ranked #1 in U.S. Credit Card Customer Satisfaction in the 2025 JD Power Study. This is the sixth consecutive year the company has taken the top spot. The study highlights especially strong satisfaction for premium and fee-based cardholders. The recognition comes as American Express refreshes benefits on its Gold Card product. For investors watching NYSE:AXP, this recognition adds another data point to the company’s premium brand story. The stock is trading at $318.69,...

Why Diamondback Energy Is On Investors’ Radar Today Diamondback Energy (FANG) is drawing fresh attention after recent share moves, with the stock showing a negative 1 day return and a mixed pattern across the past week and month. See our latest analysis for Diamondback Energy. While the latest 1 day share price return of 2.38% and 7 day share price return of 7.39% point to cooling near term momentum, the 25.01% year to date share price return and 43.66% 1 year total shareholder return show...

Gibraltar Industries (ROCK) opened Q1 2026 with total revenue of US$356.3 million and a basic EPS loss of US$0.40, setting a cautious tone around the latest numbers. The company has seen quarterly revenue move from US$246.4 million and EPS of US$0.76 in Q1 2025 through a series of US$309.5 million to US$310.9 million quarters with EPS between US$0.99 and US$1.12, before landing at US$268.7 million and EPS of US$0.40 in Q4 2025. This gives investors a clear look at how the top line has...

MGIC Investment Corporation recently reported its first-quarter 2026 results, with revenue of US$297.08 million and net income of US$165.3 million, both lower than the same period a year earlier. Despite the revenue and profit declines, MGIC’s basic and diluted earnings per share from continuing operations held around US$0.76, indicating stable per-share profitability even as overall earnings softened. Now we’ll examine how this combination of lower revenue but steady earnings per share...